A Conversation With Anita Howe, PhD

published on February 16, 2017 in Healio

In this issue, HCV Next asks five questions of Anita Howe, PhD, scientific leader for hepatitis C at the British Columbia Center for Excellence for HIV/AIDS.

Howe completed her PhD in Medical Microbiology and Immunology at the University of Alberta, Canada. Her main area of focus was nucleoside inhibitors against hepatitis B virus. A fellowship at Harvard Medical School followed. It was here that she contributed to the discovery of small molecule inhibitors of the HCV helicase while working at the Schering-Plough Research Institute, which later became Merck. From there she moved on to Wyeth Research in the role of group leader/director, and later as director of Translational Medicine. Her work at Wyeth yielded advances in a number of molecules from discovery to the clinic along with the creation of a protein biomarker laboratory with mass-spectrometry-based platforms.

Howe joined Tibotec in 2008, where she served as director of Early Development. Prior to joining the BC Center for Excellence, she served as the Hepatitis C Franchise Lead for Basic Research at Merck where her main focus was antiviral resistance for boceprevir, vaniprevir, grazoprevir, elbasvir and other drug candidates.

Who has had the greatest influence on your career?

Lorne Tyrrell, MD, of the Department of Medical Microbiology and Immunology at the Li Ka Shing Institute of Virology, who was my PhD thesis supervisor; and my mother. They both have one thing in common: dedication and determination. For Lorne, it was his dedication to his patients and students. For my mom, it was her devotion to her children. I have seen them going through hard times, but they remained steadfast to their goals and unswerving from what they set out to do.

What was the defining moment that led to your field?

I remember the first day of graduate school when Dr. Tyrrell asked me to put on a clean lab coat and follow him to see patients at the University of Alberta Hospital. Many of these patients were HIV infected. They were very weak and pale; some were so fragile that they looked like a skeleton lying on a pile of white linens. At the end of the day, Dr. Tyrrell said, “I want you to remember why you are doing your PhD.” This has stuck with me throughout my career.

View the full article >>

Tags:

Hepatitis

Treatment as Prevention®

BC Centre for Excellence in HIV/AIDS

Search form

A Conversation With Anita Howe, PhD

Search form